Vildagliptin (LAF237)

DRUG4 trials

Sponsors

Novartis, Novartis Pharmaceuticals

Conditions

HealthyType 2 DiabetesType 2 Diabetes Mellitus (T2DM)

Phase 1

Bioequivalence of Vildagliptin Tablet Manufactured in China Compared to Imported Vildagliptin Tablet in Chinese Healthy Volunteers

CompletedNCT00414947

NovartisHealthy

Start: 2006-12-31Target: 30Updated: 2007-06-22

Safety, Tolerability, Effect of Vildagliptin and How the Body Changes the Blood Level of Vildagliptin in Healthy Chinese Volunteers

CompletedNCT00419887

NovartisHealthy

Start: 2006-09-30Target: 60Updated: 2007-06-22

Phase 4

Drug Interaction of Vildagliptin (LAF237) With Voglibose in Japanese Patients With Type 2 Diabetes

CompletedNCT01309698

Novartis PharmaceuticalsType 2 Diabetes

Start: 2011-02-28Updated: 2020-12-19

Study of Efficacy and Safety of Vildagliptin as add-on Insulin Therapy in T2DM Patients

CompletedNCT02002221

Novartis PharmaceuticalsType 2 Diabetes Mellitus (T2DM)

Start: 2013-12-31End: 2015-02-28Updated: 2016-03-01

Related Papers

Efficacy and Safety of Vildagliptin as an Add-on to Insulin with or without Metformin in Japanese Patients with Type 2 Diabetes Mellitus: A 12-week, Double-Blind, Randomized Study.

2015-11-3014 citations